Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Neoplasms 1Advanced Solid Tumors 1

Interventions

pembrolizumab 3Carboplatin 3Nivolumab 2Injections 2Docetaxel 2Cisplatin 2BMS-753493 2zimberelimab 1urelumab 1tislelizumab 1tesetaxel 1spartalizumab 1olaparib 1liposomal doxorubicin 1linifanib 1lenvatinib 1ixabepilone 1durvalumab 1avelumab 1avdoralimab 1adavosertib 1TAS-119 1Rifampin 1N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 1Maximum Tolerated Dose 1Linoleic Acids, Conjugated 1Lapatinib 1Itraconazole 1Irinotecan 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Advanced Solid Tumors × zimberelimab × Clear all
NCT04747470 2024-09-03

Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors

Gilead Sciences

Phase 1 Terminated
13 enrolled 18 charts
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡